Collaboration, License and Other Arrangements -Additional Information (Details)	1 Months Ended	3 Months Ended		12 Months Ended
	Jan. 31, 2024 USD ($)	Mar. 31, 2025 USD ($)	Mar. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2019 USD ($) target
CRISPR
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, allocation of research and development expenses, percent		40.00%
Allocation of net profits and net losses, percent		40.00%
CRISPR Therapeutics
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, right to exclusively license, number of targets | target					3
Collaborative arrangement, development and regulatory potential milestone payments maximum					$ 410,000,000.0
CRISPR JDCA
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment	$ 200,000,000
Proceeds from upfront payment		$ 12,500,000
Entrada Therapeutics
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, development and regulatory potential milestone payments maximum				$ 335,000,000.0
Milestone payment			$ 75,000,000
Zai Lab Limited
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from upfront payment		$ 10,000,000